Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI
- PMID: 36403087
- PMCID: PMC9822800
- DOI: 10.1016/j.bpj.2022.11.023
Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI
Abstract
Blood coagulation is a self-repair process regulated by activated platelet surfaces, clotting factors, and inhibitors. Tissue factor pathway inhibitor (TFPI) is one such inhibitor, well known for its inhibitory action on the active enzyme complex comprising tissue factor (TF) and activated clotting factor VII. This complex forms when TF embedded in the blood vessel wall is exposed by injury and initiates coagulation. A different role for TFPI, independent of TF:VIIa, has recently been discovered whereby TFPI binds a partially cleaved form of clotting factor V (FV-h) and impedes thrombin generation on activated platelet surfaces. We hypothesized that this TF-independent inhibitory mechanism on platelet surfaces would be a more effective platform for TFPI than the TF-dependent one. We examined the effects of this mechanism on thrombin generation by including the relevant biochemical reactions into our previously validated mathematical model. Additionally, we included the ability of TFPI to bind directly to and inhibit platelet-bound FXa. The new model was sensitive to TFPI levels and, under some conditions, TFPI could completely shut down thrombin generation. This sensitivity was due entirely to the surface-mediated inhibitory reactions. The addition of the new TFPI reactions increased the threshold level of TF needed to elicit a strong thrombin response under flow, but the concentration of thrombin achieved, if there was a response, was unchanged. Interestingly, we found that direct binding of TFPI to platelet-bound FXa had a greater anticoagulant effect than did TFPI binding to FV-h alone, but that the greatest effects occurred if both reactions were at play. The model includes activated platelets' release of FV species, and we explored the impact of varying the FV/FV-h composition of the releasate. We found that reducing the zymogen FV fraction of this pool, and thus increasing the fraction that is FV-h, led to acceleration of thrombin generation.
Copyright © 2022 Biophysical Society. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests K.L. received research support from Novo Nordisk.
Figures





Similar articles
-
Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.J Biol Chem. 2017 Jun 2;292(22):9335-9344. doi: 10.1074/jbc.M116.769570. Epub 2017 Apr 18. J Biol Chem. 2017. PMID: 28420729 Free PMC article.
-
Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor.Blood. 1994 Aug 15;84(4):1132-42. Blood. 1994. PMID: 8049429
-
Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II.J Biol Chem. 1997 Feb 14;272(7):4367-77. doi: 10.1074/jbc.272.7.4367. J Biol Chem. 1997. PMID: 9020158
-
Tissue factor pathway.Baillieres Clin Haematol. 1994 Sep;7(3):469-84. doi: 10.1016/s0950-3536(05)80094-0. Baillieres Clin Haematol. 1994. PMID: 7841596 Review.
-
Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S.J Thromb Haemost. 2017 Jul;15(7):1241-1250. doi: 10.1111/jth.13665. J Thromb Haemost. 2017. PMID: 28671348 Review.
Cited by
-
Inhibition of platelet-surface-bound proteins during coagulation under flow II: Antithrombin and heparin.Biophys J. 2023 Jan 3;122(1):230-240. doi: 10.1016/j.bpj.2022.10.038. Epub 2022 Nov 2. Biophys J. 2023. PMID: 36325617 Free PMC article.
-
Examining downstream effects of concizumab in hemophilia A with a mathematical modeling approach.J Thromb Haemost. 2025 Feb;23(2):480-491. doi: 10.1016/j.jtha.2024.10.028. Epub 2024 Nov 12. J Thromb Haemost. 2025. PMID: 39536817 Free PMC article.
-
Studying the Effects of Oral Contraceptives on Coagulation Using a Mathematical Modeling Approach.Math Model Womens Health (2024). 2024;155:83-132. doi: 10.1007/978-3-031-58516-6_4. Epub 2024 Mar 28. Math Model Womens Health (2024). 2024. PMID: 40831646 Free PMC article. No abstract available.
-
The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency.Int J Mol Sci. 2023 Mar 26;24(7):6243. doi: 10.3390/ijms24076243. Int J Mol Sci. 2023. PMID: 37047215 Free PMC article. Review.
-
Mathematical modeling identifies clotting factor combinations that modify thrombin generation in normal and factor VIII-, IX-, or XI-deficient blood.Res Pract Thromb Haemost. 2024 Sep 12;8(7):102570. doi: 10.1016/j.rpth.2024.102570. eCollection 2024 Oct. Res Pract Thromb Haemost. 2024. PMID: 39434958 Free PMC article.
References
-
- Camerer E., Kolstø A.B., Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb. Res. 1996;81:1–41. https://linkinghub.elsevier.com/retrieve/pii/004938489500209X - PubMed
-
- Furie B., Furie B.C. Molecular and cellular biology of blood coagulation. N. Engl. J. Med. 1992;326:800–806. - PubMed
-
- Maroney S.A., Ellery P.E., Mast A.E. Alternatively spliced isoforms of tissue factor pathway inhibitor. Thromb. Res. 2010;125:S52–S56. https://linkinghub.elsevier.com/retrieve/pii/S0049384810000915 - PMC - PubMed
-
- Novotny W.F., Girard T.J., et al. Broze G.J. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood. 1988;72:2020–2025. https://ashpublications.org/blood/article/72/6/2020/166184/Platelets-sec... - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous